A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Open accessAbstract
CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ketamine's strong antidepressant effects were later confirmed in treatment-resistant depression and bipolar disorder.
“Shortly thereafter, ketamine's robust antidepressant effects were confirmed in treatmentresistant depression (TRD) and bipolar disorder (BD) [5][6][7]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [7]
The COMMENT section reports a robust antidepressant response to ketamine in treatment-resistant depression. The PATIENT SELECTION section says patients with bipolar disorder were excluded, so this paper does not support the bipolar-disorder part of the sentence. (LLM, conf=0.91)
Experimental — accuracy not yet measuredPsychedelics produce sustained therapeutic effects following a single administration.
“Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
The Conclusions report antidepressant effects lasting one week after a single intravenous dose of an NMDA antagonist, and the COMMENT identifies the drug as ketamine. The trial supports that finding for ketamine in treatment-resistant major depression, but does not establish sustained therapeutic effects for psychedelics as a broader group. (LLM, conf=0.85)
Experimental — accuracy not yet measuredUnlike traditional antidepressants, psychoplastogens produce both fast-acting and sustained beneficial behavioral effects after a single administration.
“Unlike traditional antidepressants, psychoplastogens produce both fast-acting and sustained beneficial behavioral effects after a single administration (Figure 1) (38–42).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
The Conclusions report that one intravenous dose of ketamine produced antidepressant effects within two hours that remained significant for a week. The Comment contrasts this response with the slower effects of traditional antidepressants. This trial supports the claim for ketamine in treatment-resistant depression, but does not establish it for psychoplastogens as a class or for beneficial behavioral effects generally. (LLM, conf=0.85)
Experimental — accuracy not yet measuredKetamine, a rapid-acting dissociative agent, is known to increase BDNF levels.
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [37]
The Comment section reports a rapid antidepressant response to ketamine in treatment-resistant depression, supporting that part of the citing sentence. Our copy does not report that ketamine increases BDNF levels; searches for BDNF and brain-derived neurotrophic factor found no such result. Page numbers were not available in the indexed passages. (LLM, conf=0.88)
Experimental — accuracy not yet measuredOther NMDAR antagonists do not show antidepressant effects.
“However, other NMDAR antagonists do not show antidepressant effects (Zarate et al., 2006)”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
The COMMENT section reports that one other NMDA receptor antagonist, oral memantine, did not show antidepressant effects in a controlled study. The claim overgeneralizes that finding: the paper also reports antidepressant effects of NMDA receptor antagonists in many animal models and says more selective antagonists need testing in patients. Page numbers are unavailable in our copy. (LLM, conf=0.89)
Experimental — accuracy not yet measured
A single low-dose ketamine treatment elicits sustained antidepressant effects lasting more than 1 week in patients.
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
The EFFICACY section reports that a single ketamine infusion produced improvement through day 7, and that two subjects maintained a response for at least two weeks. The claim's unqualified duration of more than one week overstates the general finding: only two subjects were reported to maintain a response that long. (LLM, conf=0.85)
Experimental — accuracy not yet measuredA single dose of ketamine alleviates depressive symptoms within hours in patients who have failed to respond to two or more conventional antidepressants, and the effects are sustained for 7 to 10 days.
“A single dose of ketamine alleviates depressive symptoms within hours in patients who have failed to respond to two or more conventional antidepressants, and the effects are sustained for 7 to 10 days.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
Patient Selection required participants to have failed at least two adequate antidepressant trials. The Comment and Efficacy sections report improvement within hours and a statistically significant effect through day 7, but the study did not assess whether the effect was sustained to day 10. Only 35% of ketamine-treated subjects maintained a treatment response for at least one week. (LLM, conf=0.90)
Experimental — accuracy not yet measuredKetamine's anxiolytic effects have been supported by placebo-controlled trials which demonstrated that the psychic anxiety item on the 21-item HAM-D significantly improved after ketamine infusion compared to saline; the psychic anxiety item was one of only four items to improve.
“Ketamine's anxiolytic effects have also been supported by placebo-controlled trials which demonstrated that the psychic anxiety item on the 21item HAM-D significantly improved after ketamine infusion (compared to saline); the psychic anxiety item was one of only four items to improve (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredA power analysis based on ketamine's antidepressant effects was used to determine the sample size of 18.
“A power analysis based on ketamine's antidepressant effects was used to determine the sample size of 18 (Murrough et al, 2013a;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The Efficacy and Comment sections report ketamine’s antidepressant effects, including effect sizes, which could inform a later power analysis. But this paper does not report a power analysis determining a sample size of 18; Patient Selection says its own study initially planned to include 22 patients and describes an interim analysis. (LLM, conf=0.86)
Experimental — accuracy not yet measuredKetamine induces similar immediate antidepressant response rates to psilocybin (71% at 28 hours for ketamine vs. 69% at 48 hours for psilocybin).
“which induce similar immediate antidepressant response rates (71% at 28 hours for ketamine vs. 69% at 48 hours for psilocybin) 94”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
The EFFICACY section reports that 12 of 17 ketamine-treated subjects (71%) met response criteria one day after infusion. It does not give that rate at 28 hours or report a 69% psilocybin response at 48 hours, so this paper alone does not support the comparison. (LLM, conf=0.88)
Experimental — accuracy not yet measuredKetamine, an N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
Ketamine exhibits rapid onset and robust short-term antidepressant effect in patients with treatment-resistant depression.
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [2]
Ketamine at a dose of 0.5mg/kg has consistently been shown to have robust and rapid antidepressant effects.
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [7]
Several clinical studies suggest that ketamine may also have significant anxiolytic effects.
“Several clinical studies suggest that ketamine may also have significant anxiolytic effects.”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Ketamine has anxiolytic effects in patients with major depression.
“The results of the study are consistent with previous work suggesting that ketamine has anxiolytic effects in patients with major depression (Salvadore et al, 2009;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Several studies have demonstrated the efficacy of ketamine for treatment-resistant depression.
“Several studies have demonstrated the efficacy of ketamine for treatment-resistant depression (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The lack of efficacy in this trial is likely due to the fact that most patients had mild to moderate depression as opposed to the more severe treatment-resistant major depression studied in ketamine clinical trials.
“The lack of efficacy in our trial is likely due the fact that in our study most patients had mild to moderate depression as opposed to the more severe treatment-resistant major depression studied in ketamine clinical trials (Murrough et al, 2013a;Murrough et al, 2013b;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Intravenous ketamine administered at subanesthetic doses exhibits robust and rapid onset of efficacy in patients with treatment-resistant depression.
“Intravenous ketamine administered at subanesthetic doses was found to exhibit robust and rapid onset of efficacy in patients with treatment-resistant depression (9).”
Ketamine typically does not produce the sustained antidepressant response of psilocybin (35% at week 1 for ketamine vs. 71% at 1 month for psilocybin).
“whereas it typically does not produce the sustained antidepressant response of psilocybin (35% at week 1 for ketamine vs. 71% at 1 month for psilocybin). 73,94,95”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
Subsequent randomized controlled trials replicated a 60-70% response rate of ketamine in treatment-resistant depression populations.
“Subsequent randomized controlled trials (RCTs) replicated this finding, demonstrating a 60–70% response rate of ketamine in TRD populations.10–14”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
Ketamine's antidepressant properties are transient, lasting an average of 1 week following a single infusion and 18-19 days following repeated infusions.
“However, ketamine’s antidepressant properties are also transient, lasting an average of 1 week following a single infusion10–14 and 18–19 days following repeated infusions.15,16”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms and in some clinical trials.
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
Comparable results have been replicated in several similarly designed RDBPCTs examining single administration of sub-anesthetic dose ketamine in patients with MDD and TRD.
“Comparable results have been replicated in several similarly designed RDBPCTs examining single administration of sub-anesthetic dose ketamine in patients with MDD and TRD [73,91,92,93].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
Ketamine produces rapid, robust antidepressant, antianhedonic, and antisuicidal effects within two hours, sustained at least seven days after a single infusion or intranasal dose in major depression.
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [130]
Ketamine's therapeutic effects occur within hours, with the strongest effect sizes observed at one day post-administration.
“Ketamine’s therapeutic effects occur within hours, with the strongest effect sizes observed at one day post-administration (Zarate et al., 2006).”
From Clinical indicators of the suicide crisis and response to ketamine (2025) · cites this paper as Zarate et al., 2006
A single, intravenous or intranasal sub-anesthetic dose of ketamine produces a rapid onset of antidepressant response that can last several days in the majority of treatment resistant unipolar and bipolar depressed patients.
“A single, intravenous or intranasal sub-anesthetic dose of ketamine, a non-competitive NMDA glutamate receptor channel blocker, produces a rapid onset of antidepressant response that can last several days in the majority of treatment resistant unipolar and bipolar depressed patients participating in a growing number of clinical trials148–150.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [150]
A single sub-anesthetic dose of ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
A subsequent double-blind randomized clinical trial demonstrated efficacy of ketamine in treatment-resistant major depressed patients who failed at least two conventional antidepressant treatments.
“A subsequent double-blind randomized clinical trial demonstrated the efficacy of ketamine in treatment-resistant major depressed patients, who failed at least two conventional antidepressant treatments 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
In that trial, antidepressant effects manifested within 2 hours post-infusion and 35% of patients maintained response for at least 7 days.
“The antidepressant effects of ketamine manifested within 2 hours post-infusion and 35% of patients maintained response for at least 7 days 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · see citing works
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217 · see citing works
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · see citing works
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,834 · see citing works
A Growing Edge of Measurement of Feelings [ Abridged ]
Aitken, R. C. B. (1969) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576906201005 · Cited by 1,531 · see citing works
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422 · see citing works
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054 · see citing works
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R. V., Epperson, C. N., Wu, Y., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796 · see citing works
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · see citing works
(2001) · PubMed · Cited by 780 · see citing works
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604 · see citing works
Vetulani, J., & Sulser, F. (1975) · Nature · doi:10.1038/257495a0 · Cited by 596 · see citing works
Antidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 587 · see citing works
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553 · see citing works
Self-citationManji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K. D., Gray, N. A., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 499 · see citing works
Self-citationInitiation and adaptation: a paradigm for understanding psychotropic drug action
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.2.151 · Cited by 490 · see citing works
Husain, M. M., Rush, A. J., Fink, M., Knapp, R. G., Petrides, G., Rummans, T. A., Biggs, M. M., O’Connor, K. M., Rasmussen, K. G., Litle, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0406 · Cited by 455 · see citing works
Sleep deprivation in depression: what do we know, where do we go?
Wirz-Justice, A., & Van den Hoofdakker, R. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00125-0 · Cited by 429 · see citing works
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · see citing works
Self-citationCOMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERS
White, P. F., Schüttler, J., Shafer, A., Stanski, D. R., Horai, Y., & Trevor, A. J. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.2.197 · Cited by 416 · see citing works
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387 · see citing works
Self-citationAntidepressants for the new millennium.
Skolnick, P. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00330-1 · Cited by 372 · see citing works
Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments
Coyle, J. T., & Duman, R. S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00195-8 · Cited by 357 · see citing works
Skolnick, P., Layer, R. T., Popik, P., Nowak, G., Paul, I. A., & Trullás, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979537 · Cited by 344 · see citing works
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J. A., Sporn, J., Denicoff, K. K., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324 · see citing works
Self-citationKrystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317 · see citing works
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304 · see citing works
Papp, M., & Moryl, E. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90516-9 · Cited by 272 · see citing works
Zarate, C. A., Quiroz, J. A., Singh, J. B., Denicoff, K. D., Jesus, G. D., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.023 · Cited by 257 · see citing works
Self-citationInteraction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, σ and Muscarinic Receptors
Hustveit, O., Maurset, A., & Øye, I. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb01041.x · Cited by 246 · see citing works
Entsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245 · see citing works
Prolonged effect of an anesthetic dose of ketamine on behavioral despair
Yılmaz, A., Schulz, D., Aksoy‐Aksel, A., & Canbeyli, R. S. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00693-1 · Cited by 199 · see citing works
Lindefors, N., Barati, S., & O'Connor, W. T. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00255-2 · Cited by 178 · see citing works
Clozapine and Haloperidol in Moderately Refractory Schizophrenia
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A. Z., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178 · see citing works
Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders
Zarate, C. A., Du, J., Quiroz, J. A., GRAY, N. A., Denicoff, K. D., Singh, J., Charney, D. S., & Manji, H. K. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.017 · Cited by 164 · see citing works
Self-citationPotential Antidepressive Properties of Amantadine, Memantine and Bifemelane
Moryl, E., Danysz, W., & Quack, G. (1993) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1993.tb01351.x · Cited by 157 · see citing works
Boyer, P., Skolnick, P., & Fossom, L. H. (1998) · Journal of Molecular Neuroscience · doi:10.1007/bf02761776 · Cited by 157 · see citing works
Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)
Layer, R. T., Popik, P., Olds, T., & Skolnick, P. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00155-p · Cited by 137 · see citing works
Current perspectives on the development of non-biogenic amine-based antidepressants
Skolnick, P., Legutko, B., Li, X., & Bymaster, F. P. (2001) · Pharmacological Research · doi:10.1006/phrs.2000.0806 · Cited by 132 · see citing works
Elliott, K. J. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00083-p · Cited by 132 · see citing works
DeBattista, C., Posener, J. A., Kalehzan, B. M., & Schatzberg, A. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1334 · Cited by 113 · see citing works
Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients
Marangell, L. B. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830150034007 · Cited by 111 · see citing works
Przegaliński, E., Tatarczynska, E., Dereń-Wesołek, A., & Chojnacka-Wójcik, E. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00157-8 · Cited by 111 · see citing works
Zarate, C. A., Quiroz, J. A., Quiroz, J. A., Manji, H. K., Payne, J. L., Kornstein, S. G., Manji, A. H. K., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4204 · Cited by 104 · see citing works
Self-citationDeterminants of trapping block of N‐methyl‐ d ‐aspartate receptor channels
Bolshakov, K. V., Гмиро, В. Е., Tikhonov, D. B., & Magazanik, L. G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01956.x · Cited by 98 · see citing works
Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats
Meloni, D., Gambarana, C., Montis, M. G. D., Pra, P. D., Taddei, I., & Tagliamonte, A. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90374-3 · Cited by 96 · see citing works
Smith, D. J., Azzaro, A. J., Zaldivar, S. B., Palmer, S., & Lee, H. S. (1981) · Neuropharmacology · doi:10.1016/0028-3908(81)90015-0 · Cited by 90 · see citing works
NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury
Wang, C., & Shuaib, A. M. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007053544183 · Cited by 62 · see citing works
Kapur, S., & Seeman, P. M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01110-6 · Cited by 62 · see citing works
Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents.
Rothman, S. M. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20992-2 · Cited by 45 · see citing works
Antidepressants and the Risk of Suicidal Behaviors
MAANY, I. (2004) · JAMA · doi:10.1001/jama.292.23.2833-b · Cited by 45 · see citing works
Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons
Maler, J. M., Esselmann, H., Wiltfang, J., Kunz, N., Lewczuk, P., Reulbach, U., Bleich, S., Rüther, E., & Kornhuber, J. (2005) · Brain Research · doi:10.1016/j.brainres.2005.06.017 · Cited by 44 · see citing works
Modulation of glutamate receptors: Strategies for the development of novel antidepressants
Skolnick, P. (2002) · Amino Acids · doi:10.1007/s00726-001-0121-7 · Cited by 43 · see citing works
Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine
Vry, J. D., & Jentzsch, K. R. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200305000-00007 · Cited by 43 · see citing works
Antidepressants and the Risk of Suicidal Behaviors
Maany, I. (2004) · JAMA · doi:10.1001/jama.292.23.2833-a · Cited by 37 · see citing works
Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs
Byrd, L. D., Standish, L. J., & Howell, L. L. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90386-4 · Cited by 31 · see citing works
Narita, M., Yoshizawa, K., Nomura, M., Aoki, K., & Suzuki, T. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01089-5 · Cited by 25 · see citing works
Elliott, K. J., Kest, B., Man, A. J., Kao, B., & Inturrisi, C. E. (1995) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380294 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [7]7. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobi- ology of depression. Neuron. 2002;34:13-25.
- [27]27. First MB, Spitzer RL, Gibbon M, Williams AR. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
- [33]33. Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62:989-993.
- [42]42. Zarate CAJ, Singh J, Quiroz J, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind placebo-controlled study of memantine in ma- jor depression. Am J Psychiatry. 2006;163:153-155.
Cited by
Sorted by citations
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,501 · see citing works
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · see citing works
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · see citing works
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · see citing works
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166 · see citing works
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · see citing works
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · see citing works
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · see citing works
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · see citing works
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · see citing works
Self-citationBrain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390 · see citing works
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · see citing works
Self-citationNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · see citing works
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · see citing works
Self-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · see citing works
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · see citing works
Self-citationLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082 · see citing works
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036 · see citing works
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036 · see citing works
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · see citing works
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959 · see citing works
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · see citing works
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · see citing works
Self-citationInflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926 · see citing works
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · see citing works
Self-citationMajor depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · see citing works
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894 · see citing works
Self-citationPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · see citing works
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · see citing works
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · see citing works
Self-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · see citing works
Self-citationDopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754 · see citing works
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X.-M., Nathan, P. J., & Wren, P. B. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3505 · Cited by 747 · see citing works
Lipton, J. O., & Şahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 732 · see citing works
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · see citing works
Self-citationThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · see citing works
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714 · see citing works
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · see citing works
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · see citing works
Self-citationStructure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686 · see citing works
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676 · see citing works
Self-citationThe organization of the stress system and its dysregulation in depressive illness
Gold, P. W. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.163 · Cited by 654 · see citing works
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663 · see citing works
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · see citing works
Morgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667 · see citing works
Linking Molecules to Mood: New Insight Into the Biology of Depression
Krishnan, V., & Nestler, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.10030434 · Cited by 643 · see citing works
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 643 · see citing works
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 629 · see citing works
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614 · see citing works
Gliogenesis and Glial Pathology in Depression
Rajkowska, G., & Miguel-Hidalgo, J. J. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780619326 · Cited by 612 · see citing works
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613 · see citing works
Self-citationA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 611 · see citing works
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609 · see citing works
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605 · see citing works
Pathophysiology of depression: do we have any solid evidence of interest to clinicians?
HASLER, G. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00298.x · Cited by 604 · see citing works
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · see citing works
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · see citing works
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594 · see citing works
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 599 · see citing works
Daskalakis, N. P., Bagot, R. C., Parker, K. J., Vinkers, C. H., & de Kloet, E. R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.06.008 · Cited by 579 · see citing works
Rapid effects of deep brain stimulation for treatment-resistant major depression
Schlaepfer, T. E., Bewernick, B. H., Kayser, S., Mädler, B., & Coenen, V. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.034 · Cited by 563 · see citing works
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · see citing works
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · see citing works
Self-citationSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558 · see citing works
General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis
Brown, E. N., Purdon, P. L., & Dort, C. J. V. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153200 · Cited by 551 · see citing works
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538 · see citing works
Cognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535 · see citing works
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · see citing works
Self-citationPreskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 522 · see citing works
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · see citing works
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519 · see citing works
Ketamine for chronic pain: risks and benefits
Niesters, M., Martini, C. H., & Dahan, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12094 · Cited by 514 · see citing works
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, Ç., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493 · see citing works
Wang, M., Yang, Y., Wang, C.-J., Gamo, N. J., Jin, L. E., Mazer, J. A., Morrison, J. H., Wang, X.-J., & Arnsten, A. F. T. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.032 · Cited by 489 · see citing works
The role of 5-HT receptors in depression
Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017) · Molecular Brain · doi:10.1186/s13041-017-0306-y · Cited by 485 · see citing works
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · see citing works
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482 · see citing works
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482 · see citing works
Self-citationBrexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479 · see citing works
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466 · see citing works
Self-citationNeurobiological mechanisms in major depressive disorder
Rot, M. A. H., Mathew, S. J., & Charney, D. S. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080697 · Cited by 473 · see citing works
Self-citationLoftus, R. W., Yeager, M. P., Clark, J. A., Brown, J. R., Abdu, W. A., Sengupta, D. K., & Beach, M. L. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181e90914 · Cited by 471 · see citing works
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · see citing works
Self-citationSigtermans, M. J., van Hilten, J. J., Bauer, M. C. R., Arbous, M. S., Marinus, J., Sarton, E. Y., & Dahan, A. (2009) · Pain · doi:10.1016/j.pain.2009.06.023 · Cited by 468 · see citing works
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460 · see citing works
Banasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458 · see citing works
Ketamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455 · see citing works
Self-citationGarcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454 · see citing works
Lucassen, P. J., Pruessner, J. C., Sousa, N., Almeida, O. F. X., Dam, A. M. V., Rajkowska, G., Swaab, D. F., & Czéh, B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1223-5 · Cited by 449 · see citing works
Glutamatergic Mechanisms Associated with Seizures and EpilepsyPreprint
Barker‐Haliski, M. L., & White, H. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022863 · Cited by 444 · see citing works
The Role of BDNF on Neural Plasticity in Depression
Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., Yu, S., & Liu, H. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00082 · Cited by 435 · see citing works
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · see citing works
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431 · see citing works
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 431 · see citing works
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426 · see citing works
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · see citing works
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422 · see citing works
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · see citing works
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396 · see citing works
- Authors
- Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K.
- Affiliations
- National Institutes of Health (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-01
- Volume
- 63
- Issue
- 8
- Pages
- 856
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109334244
- Semantic Scholar
- 3e83c317059846d97106b64a4befc4c24b87e3d1
- Cited by
- 3,766
- References
- 62
- Citations by year
- 2026: 125 · 2025: 186 · 2024: 240 · 2023: 197 · 2022: 222 · 2021: 249 · 2020: 404 · 2019: 229 · 2018: 233 · 2017: 202 · 2016: 237 · 2015: 223 · 2014: 190 · 2013: 206 · 2012: 159
- FWCI
- 48.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, NMDA receptor antagonists, treatment-resistant depression, major depressive disorder, rapid antidepressant effects, intravenous infusion, glutamatergic system, antidepressant onset of action, remission
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Cross-Over Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
